CorMedix Inc. (CRMD) Stock Score, Valuation & Financial Research
CorMedix Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 83/100.
Quick answer for CRMD
CorMedix Inc. currently has a Wall Street Score of 83/100. The stored market price is $7.82. Its financial score is 62/100. Its valuation score is 100/100. The latest WSS change is +0.2 points. These figures are a research snapshot, not a buy or sell recommendation.
What CorMedix Inc. does
CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution. This treatment aims to diminish and avert catheter-related infections and blood clots in patients who utilize central venous catheters for medical procedures such as hemodialysis, total parenteral nutrition, and oncology care. Incorporated in 2006, the company initially operated as Picton Holding Company, Inc. until officially adopting the name CorMedix Inc. in January 2007. Its corporate headquarters are located in Berkeley Heights, New Jersey.
CRMD financial snapshot
- Wall Street Score:
- 83/100
- Current price:
- $7.82
- Market capitalization:
- $613.5M
- Revenue:
- $462.2M
- Net income:
- $187.2M
- Free cash flow:
- $172.8M
- Cash:
- $256.7M
- Total debt:
- $145.2M
- EPS:
- 2.41
- P/E ratio:
- 3.2x
- Financial score:
- 62/100
- Valuation score:
- 100/100
- Revenue score:
- 0/100
What stands out
- Reported year-over-year revenue growth is +0.5%.
- Free cash flow is $172.8M, showing positive cash generation.
- The balance sheet shows $256.7M of cash versus $145.2M of total debt, leaving more cash than debt.
- The latest Wall Street Score change is +0.2 points: CRMD increased 0.2 points because overall fundamentals improved.
- The current research record carries a missing revenue history warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 100/100, which Wall Street Score classifies as strong within the model's valuation framework.
The financial score is 62/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-17.
How to research CRMD
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.